

# Creation and potentiation of a lipid-armored ovarian cancer vaccine

## Project Description

Project duration:	Honours project; ~9 months
Description:	<p>Are you passionate about cancer research and eager to make a significant impact in the field of immunotherapy? Join our team for a unique Honours project focused on enhancing the stimulatory properties of human Type I Dendritic Cells (cDC1s) using advanced mRNA electroporation techniques to combat ovarian cancer.</p> <p>This project offers you the opportunity to:</p> <ul style="list-style-type: none"> <li>• <b>Explore Advanced mRNA Technology:</b> Learn and apply state-of-the-art mRNA modifications to increase immunogenicity and improve dendritic cell functionality.</li> <li>• <b>Hands-On Laboratory Experience:</b> Gain proficiency in electroporation, cell culture, T cell assays, flow cytometry and immune cell manipulation, essential skills for a career in biomedical research.</li> <li>• <b>Impactful Research:</b> Contribute to groundbreaking studies aimed at enhancing the immune response against ovarian cancer, potentially leading to new therapeutic strategies.</li> <li>• <b>Collaborative Environment:</b> Work alongside experienced researchers and clinicians in a supportive, interdisciplinary team at the forefront of cancer immunotherapy.</li> </ul> <p>Join us in this transformative project where your research could pave the way for novel cancer treatments.</p>
Expected outcomes and deliverables:	<p>With help from the Cancer Immunotherapies Team, you will:</p> <ol style="list-style-type: none"> <li>1. Expand human cDC1 from ovarian cancer samples and umbilical cord blood</li> <li>2. Optimize a protocol for the electroporation of nucleic acids and tumor cell lysate in human cDC1</li> <li>3. Electroporate DC1 with tumor cell lysate and messenger RNA (mRNA) encoding gene/s which confer resistance to enriched lipids within the ovarian cancer microenvironment. Alternately, utilize CRISPR/Cas9 to knockout genes which confer immunosuppressive functions to DC1 after lipid contact.</li> <li>4. Evaluate the ability of modified cDC1 to stimulate T cells <i>in vitro</i>; utilize multiple measures of T cell functionality including intracellular cytokine staining and killing assays.</li> </ol>
Suitable for:	<p>Students with an interest in cancer immunotherapy research and undergraduate courses completed to a high standard in immunology, cell &amp; molecular biology, microbiology and biochemistry subjects are encouraged to apply. Students with a Bachelor of Science, Bachelor of Biomedical Science, Bachelor of Biotechnology or related degree are welcome. Experience in a research environment is desired but not essential. Ideal candidates are dedicated, detail-oriented, and have a strong background in molecular biology or immunology.</p>
Primary Supervisor:	<p>Kristen Radford - <a href="mailto:kristen.radford@mater.uq.edu.au">kristen.radford@mater.uq.edu.au</a>  Liam O'Brien - <a href="mailto:liam.obrien@mater.uq.edu.au">liam.obrien@mater.uq.edu.au</a></p>